Acute Health Effects Due to Ultrafine Particles From Candles and Cooking (Ultrafine)

November 4, 2020 updated by: Torben Sigsgaard, University of Aarhus

THE ULTRAFINE PROJECT - A Study of Acute Health Effects of Exposure to Particles Generated by Candles and Cooking

People spend up to 90% of their life indoor, and the way we live and behave in our homes has substantial effects on our health and well-being. Particle contamination is suggested to have substantial negative effects on health, with candles and cooking emitting the largest amount of particles, thus being the largest contributors to indoor air pollution.

The overall aim of the present project is to contribute to increased understanding of the association between indoor particulate air pollution and health and well-being.

Study Overview

Detailed Description

Introduction: People spend up to 90% of their life indoor, and the way we live and behave in our homes has substantial effects on our health and well-being. Particle contamination is suggested to have substantial negative effects on health, with candles and cooking emitting the largest amount of particles, thus being the largest contributors to indoor air pollution. Little is known about the potential adverse health effects of candles and cooking, and people with asthma may be more susceptible.

Aim: To investigate local and systemic effects of short-term exposure to lit candles and cooking among young asthmatics.

Design: In a randomised double-blinded cross-over study non-smoking asthmatics (18-25 years) were exposed for five hours at three different exposure conditions separated by 14 days; A) clean filtered air, B) lit candles and C) cooking emissions under controlled environmental conditions.

Measurements: TSI P-TRAK Ultrafine Particle Counter was used for particle counts. Health effects, including lung function (FEV1/FVC) and fraction of exhaled nitric oxide (FeNO) were evaluated in relation to local and systemic effects prior to, right after and 24 h. after exposure.

Analysis: Mixed methods approach taking both time and exposure into account.

Study Type

Interventional

Enrollment (Actual)

36

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Central Region Denmark
      • Aarhus, Central Region Denmark, Denmark, 8000
        • Climate Chambers, Dept. Public Health, Aarhus University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

15 years to 25 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Aged 15-25
  • Medically treated / physician diagnosed mild seasonal asthma
  • Never smoker or ex-smoker ≥ 6 months
  • Allergy > 1 common allergy

Exclusion Criteria:

  • Any other disease that could influence the study parameters
  • Conditions that prevent safe access to the climate chambers (such as claustrophobia)
  • Perennial asthma
  • Need for continuous medical treatment for asthma
  • Pregnancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Sham Comparator: Clean Air
Just clean air - no exposure
Nothing but clean air
Experimental: Cooking
Four ovens were frying pork - one at a time. When the first oven finished, the next oven started and so forth for approx. 7 hours.
Generating fine and ultrafine particles from frying pork in an oven
Experimental: Candles
10 lit candles were placed at a table. Burning for approx. 7 hours with light ventilation.
Generating fine and ultrafine particles from lit candles

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Particles in Exhaled Air (Surfactant Protein A & Albumin)
Time Frame: Time Frame: At baseline (0 hour), after exposure (5 hours), and the day after exposure (24 hours)
PExA: Subjects performed repeated breath maneuvers allowing for airway closure and re-opening, and exhaled particles were optically counted and collected on a membrane using the (novel) PExA® instrument set-up.
Time Frame: At baseline (0 hour), after exposure (5 hours), and the day after exposure (24 hours)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Lung Function (FEV1 & FVC)
Time Frame: At baseline (0 hour), after exposure (5 hours), and the day after exposure (24 hours)
Spirometry
At baseline (0 hour), after exposure (5 hours), and the day after exposure (24 hours)
Change in Fractional exhaled nitric oxide (FENO)
Time Frame: At baseline (0 hour), after exposure (5 hours), and the day after exposure (24 hours)
NIOX VERO system; Aerocrine AB, Sweden
At baseline (0 hour), after exposure (5 hours), and the day after exposure (24 hours)
Change in Blood samples
Time Frame: At baseline (0 hour), after exposure (5 hours), and the day after exposure (24 hours)
Cytokines (IL-8), DNA-damages
At baseline (0 hour), after exposure (5 hours), and the day after exposure (24 hours)
Change in nasal volume (using Acoustic rhinometry)
Time Frame: At baseline (0 hour), after exposure (5 hours), and the day after exposure (24 hours)
Is used to assess the nasal cross sectional area and volume. The left and right nasal cavity were studied alternatively until three reproducible measurements were obtained. The minimum cross sectional cavity area was calculated from the means of the measurements. By integration of the area-distance curve, the sum of the volume 2 to 4 (vol2-4) from the nostril was determined on both sides.
At baseline (0 hour), after exposure (5 hours), and the day after exposure (24 hours)
Change in biomarkers in Saliva Sample
Time Frame: At baseline (0 hour), after exposure (5 hours), and the day after exposure (24 hours)
An oral svap from Salivette was placed in the mouth of the participant to collect saliva by gently chewing the swab for one minute. Afterwards the saturated swab was removed to the suspended insert and closed firmly with a lid. Then the sample was transferred to a freezer and stored for -80 C until further analysis. The sample will be analyzed for biomarkers (amylase, cortisol, substance P, lysozyme and secretory IgA.)
At baseline (0 hour), after exposure (5 hours), and the day after exposure (24 hours)
Change in Subjective Symptoms
Time Frame: Every 30 minute during 5 hours of exposure
In the exposure chamber participants were asked to fill out a symptom questionnaire every 30 minute regarding their well-being and experienced symptoms in eyes, nose and throat. The participants were asked to score their evaluation (rate the strength) of symptoms by placing a cross on a 130 mm open Visual Analogue Scale (VAS). The intensity of any discomfort was registered as the length in mm from the left of the scale to the marker. The scores were rated from 0 to 100% with highest number corresponding to highest discomfort. Health effects were evaluated in relation to rated changes in symptoms.
Every 30 minute during 5 hours of exposure

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Karin R Laursen, MSc, Department of Public Health, Aarhus Universitet

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2019

Primary Completion (Actual)

December 20, 2019

Study Completion (Actual)

December 20, 2019

Study Registration Dates

First Submitted

March 18, 2020

First Submitted That Met QC Criteria

March 18, 2020

First Posted (Actual)

March 19, 2020

Study Record Updates

Last Update Posted (Actual)

November 6, 2020

Last Update Submitted That Met QC Criteria

November 4, 2020

Last Verified

March 1, 2020

More Information

Terms related to this study

Other Study ID Numbers

  • 191100

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Asthma

Clinical Trials on Clean Air

Subscribe